Sarah Collins

UnitedHealth Group (UNH) released its Q3 2018 earnings today. UNH reported sales of $56.6 billion, up ~12.4% on a year-over-year basis.

Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.

Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.

Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.

On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.

Leerink raised its recommendation on Teva Pharmaceutical Industries from “underperform” to “market perform.”

Teva is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales.

On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.

Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

Johnson & Johnson started shipments of its revamped baby care line in July, which is expected to register improved performance in the third quarter.

Tremfya reported sales of $126 million in the second quarter, compared to $72 million in sales reported in the first quarter.

Optum has been growing at a fast pace. It expects sales growth of ~19% CAGR (compound annual growth rate) from 2011 to 2018.

Of the 24 analysts covering UNH stock, ten have recommended a “strong buy,” and 13 have recommended a “buy.”

Today, Morgan Stanley downgraded Mylan (MYL) from “overweight” to “equal weight.” The firm also cut its target price for MYL stock from $46 to $36.

On December 18, 2017, Zimmer Biomet Holdings (ZBH) announced a quarterly cash dividend of $0.24 per share for fiscal 4Q17.

On October 2, Morgan Stanley raised its target price for BSX stock. That day, BSX stock was trading at its 52-week high.

Abbott Laboratories (ABT) announced that it had received a CE mark for its high sensitivity troponin-I blood test on September 26.

On October 1, ABT announced that it had received a CE mark in Europe for its next-generation continuous glucose monitoring system, the Freestyle Libre 2.

On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.

UnitedHealth Group is a leading managed healthcare firm in the United States.

UnitedHealth Group (UNH) is one of the largest Fortune 500 companies.

Mylan announced the launch of its generic Brevibloc injection in single-dose bags on September 13.

On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the European Commission for Hulio.

On September 21, Mylan (MYL) launched its authorized generic version of Acorda Therapeutics’ Ampyra, which is used for improvement in walking for adults who have multiple sclerosis.

According to Leerink analyst Amy Fadia, Fulphila is expected to generate sales of $73.0 million in 2018. Fadia expects Fulphila’s sales to reach $260.0 million in 2019.

On September 26, Mylan had a 12-month forward PEG ratio of ~0.94x.

Align Technology was trading at its 52-week high of $398.88 on September 25. The stock reported its 52-week low of $180.31 on September 28, 2017.

Align Technology (ALGN) stock hasn’t received any recommendation updates since the stock was upgraded by several analysts in July.

On September 17, Leerink Partners raised its target price on Mylan (MYL) stock from $47.00 to $48.00.

On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.

Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.

Today, Jefferies raised its target price for Boston Scientific (BSX) stock from $42 to $45. Let’s take a closer look.

On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.

Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.

On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.

On September 27, Sanofi (SNY) had a market capitalization of $113 billion, and its stock closed at $44.84.

On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.

In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.

On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.

As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.

Teva Pharmaceutical Industries (TEVA) has seen a number of positive developments in the recent months, which have come as a sigh of relief for investors.

On September 26, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $21.96, a decline of ~5.6% compared to the previous day’s closing price.

On September 26, Abbott Laboratories (ABT) ended the trading day at $72.84, up ~0.89% from the previous day’s close.

Mylan (MYL) has exclusive commercialization rights to Atomo’s CE-marked self-test products in more than 100 countries.

Mylan (MYL) received FDA approval for Fulphila in June, and the drug was launched in the United States in July.

As of September 24, ten of the 24 analysts covering UNH stock have given it a “strong buy” recommendation.

Today, Boston Scientific (BSX) stock jumped on news of the FDA approval of its drug-eluting vascular stent system Eluvia for PAD (peripheral artery disease) treatment.

Today, Abbott Laboratories (ABT) opened trading ~2.9% higher than the previous trading day’s closing price of $68.79.

Xarelto is a blood thinner developed and commercialized by Johnson & Johnson’s (JNJ) subsidiary, Janssen, and Bayer (BAYZF).

This month, Johnson & Johnson’s (JNJ) subsidiary, Janssen, submitted a new drug application for its esketamine nasal spray for treatment-resistant depression in adults.

Johnson & Johnson is focused on strengthening its medical device technologies business.

Abbott stock has been gaining momentum recently, and its valuation has improved.

On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15.

As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).

On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.

As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.

On September 12, Hologic (HOLX) provided an update on the financial impact of the suspension of its marketing and distribution of the company’s Vitalia handpieces and probes.

Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.

The rating downgrade from Baird on September 14 triggered the downward trend in Tandem stock.

Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

On September 14, Reuters surveyed 24 analysts covering BSX stock. Of these analysts, 21 analysts gave a “buy” or “strong buy” recommendation on the stock.

With the acquisition of Aegmenix, Boston Scientific adds its SpaceOAR system to its men’s health portfolio, which is part of BSX’s MedSurg segment.

On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.

Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.

Jefferies expects Boston Scientific to report EPS of $1.60 in fiscal 2019, $1.82 in fiscal 2020, $2.09 in fiscal 2021, and $2.34 in fiscal 2022.

Today, Boston Scientific (BSX) opened at $37.11, up ~1.8% since yesterday. This is the highest level for BSX stock since October 2004.

Johnson & Johnson’s (JNJ) subsidiary Janssen Pharmaceuticals filed regulatory submissions for label expansion of its multiple myeloma drug Darzalex.

Over the last month, JNJ stock has generated increased interest due to some key product approvals and trial data announcements.

The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

On September 6, Hologic (HOLX) ended the day at $38.74.

UnitedHealth Group (UNH) has announced that its board of directors has authorized a cash dividend of $0.90 per share.

Of the 23 analysts covering UNH stock, all of them have “buy” or “strong buy” recommendations for UnitedHealth Group.

UnitedHealth Group (UNH) stock registered its 52-week high of $270.17 last week on August 30.

Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. Yesterday, SGMO stock closed at $19.05.

Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.

On September 3, Sanofi announced that it has been granted authorization by the European Commission for Cablivi (caplacizumab).

On August 31, Stryker had a consensus 12-month target price of $184.43 per share.

On August 31, Wright Medical Group had a consensus 12-month target price of $32.07 per share.

On August 30, Needham had cut its recommendation on KTWO stock from “buy” to “hold.”

Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.

Teva Pharmaceutical Industries (TEVA) received FDA (U.S. Food and Drug Administration) approval for its generic version of Mylan’s EpiPen.

Teva Pharmaceutical Industries (TEVA) has risen ~9% over the last five days.

Teva stock has gained ~27.0% year-to-date on the back of the positive news that included product launches and study data.

The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.

As of August 15, analysts’ target price for ARRY is $23.57, which implies a ~71.7% return over the next 12 months based on the stock’s August 14 price of $13.73.

Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr.

Array BioPharma (ARRY) reported its Q4 2018 and fiscal 2018 earnings results August 14. Its sales rose by ~4.9% YoY (year-over-year) to $35.4 million, missing analysts’ estimate of $38.7 million.

On June 30, Mylan’s debt-to-adjusted EBITDA multiple was 3.9x.

Mylan announced that it created a strategic review committee for the evaluation of “a wide range of alternatives to unlock the true value of our one-of-a-kind platform.”

During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.

Mylan’s Morgantown restructuring and remediation program comprises discontinuing certain products on the basis of profitability, market competition, and pricing dynamics.

In Q2 2018, Mylan (MYL) reported North America segment net sales of $1.0 billion, which represented a YoY decline of ~22%.

The closing price for Mylan (MYL) stock on August 10 was $37.21, and its market capitalization stood at $19.2 billion.

Mylan (MYL) reported its Q2 earnings on August 8. On August 13, 13 of 20 surveyed firms still held a “buy” or “strong buy” rating on MYL.

Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States.

RBC Capital Markets issued a report highlighting its bullish stance on the generic pharma industry, which is under immense pricing pressure.

Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.

Boston Scientific (BSX) announced the acquisition of Veniti for $108.0 million. BSX already owns a 25% stake in Veniti.

Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.

Mylan (MYL) plans to release its Q2 results on August 8. Thirteen of the 20 analysts covering the stock have given it a “buy” or “strong buy.”